This paper addresses the question: in Graves' disease is there a thyroid-growth stimulating IgG (TGI) separate from thyroidstimulating antibody (TSAb)? Using the functioning rat thyroid line (FRTL5) cells for TGI (incorporation of 13H1-thymidine into DNA) and TSAb (increase in cAMP concentration) assays, we tested IgG from 30 Graves' patients.
Introduction
In recent years the possibility has been raised that there may be a specific thyroid growth-stimulating IgG (TGI),1 distinct from the thyroid-stimulating antibody (TSAb) of Graves' disease, circulating in patients with simple goiter (1) (2) (3) (4) or Graves' disease (3, 5) . In addition, it was suggested that stimulation of thyroid growth may not be mediated by cAMP (1, 3, 6) unlike much of the rest of thyroid function (7) , and despite the fact that such mediation was well documented for growth effects of TSH in canine thyroid cells (8-1 1) . Recently, we addressed the question of whether TSH-stimulated growth (of the nontransformed functioning rat thyroid line, FRTL5 cells) was mediated by cAMP, and obtained data (12) , as have others (13, 14) , in support of that concept. We now describe experience with another aspect of the topic, viz., is it necessary to hypoth-esize that in Graves' disease TSAb and TGI coexist as different molecules, or might the activities reflect the properties of a single IgG?
To this end we used three assay systems: increase in cAMP in human thyroid cells (15) and in FRTL5 cells (12) and increase in the incorporation of [3H]thymidine ([3H]Tdr) into DNA in FRTL5 cells (12) . We studied IgG from 30 patients with Graves' disease, including 16 previously reported ( 16), 12 listed in Table I , one whose data are given in Fig. 2 and one whose IgG acts as our laboratory standard TSAb, the assay characteristics of which have been described (12, 15 ).
Methods
Patients. The 30 patients studied all had a diagnosis of Graves' disease established by conventional clinical and laboratory criteria ( 17) . Data from 16 of these patients were reported in brief previously (16) . The additional 14 IgG were chosen for the studies described here because of the wide ranges of responses obtained with them in the human thyroid cell assay (see Fig. 1 for results with 12 IgG). At the time blood was taken for the current investigation, the patients' clinical states varied from being hyperthyroid and freshly diagnosed to being hypothyroid but on thyroxine-replacement therapy after ablative treatment of hyperthyroidism (Table I) 
Results
Assays in human thyroid cells. These were carried out at two or three concentrations of IgG, typically 0.05, 0.5, and 1.5 mg/ml hypotonic medium, as previously described (15, 20) . All 30 samples were positive at one or more concentrations. Illustrative data with IgG from 12 patients are given in Fig. 1 . As we have emphasized in an earlier publication (20) , the response to the three doses of IgG tested may vary from straight-line positive slope (e.g., IgG 8), through biphasic (e.g., IgG 3), to a straight-line negative slope (e.g., patient 6). Also shown in the figure is the fact that the least potent IgG (1-5) were negative in the FRTL5-cAMP assay and all others were positive. This aspect of the study is enlarged below.
Assays with FRTL5 cells. Of the 30 IgG, 17 were positive in terms of both cAMP production and [3H]Tdr incorporation; 4 were low positive (< 180%) as TSAb but negative in the TGI assay; 8 were negative in both procedures; data for the 12 most recently studied IgG are in Table I . We had the opportunity to obtain repeatedly IgG from 1 patient and her data are detailed below.
There was no correlation of the data from any of the three assay systems, specifically the TGI procedure, with estimated goiter size (Table I) . On the other hand, as indicated in Table I , TGI negative IgG were also negative in the FRTL5-cAMP assay and were the least potent in the human thyroid cell assay. A correlation coefficient of 0.95, P < 0.001, resulted when the values obtained with the lowest IgG concentrations in the 12 duplicate sets of data were used to compare results of TSAb versus TGI assays. The values with the highest IgG concentrations were not as satisfactory for analysis since some represented data after the maximum responsiveness of the TGI assay was reached.
Studies with individual IgG. Fig. 5 . IgG-i had a slight negative effect by itself, and TSAb and TSH were stimulatory at 20 ug and 20 MU per ml; these effects of TSAb and TSH were completely inhibited by addition of IgG-i to the system. The mechanism of inhibition of TSAb-IgG and TSH by IgG-i in the TSAb assay was explored as shown in Fig. 6 . In this experiment cells were pre-incubated with 1 mg IgG-i or normal IgG per ml buffer for 1 h before they were washed and used for the TSAb assay. The effect of only preincubation with IgG-i was to inhibit both stimulators by > 90%; there was complete inhibition when TSH and TSAb were assayed with IgG-i included in the second incubation. Similar results were obtained when another inhibitory IgG was tested in like fashion (data not shown).
Discussion
These experiments were aimed at testing the hypothesis that there may be different IgG molecules in Graves' disease that are active in TSAb and TGI assays. Our findings are compatible with the view that the same IgG is active in both systems.
As emphasized previously we consider it important, when using human thyroid cells, to assay samples for TSAb at sev- (Fig. 1) that occur more frequently with the former. In our experience, a response in the human system of at least 400% increase in cAMP with one concentration of IgG was obtained if that IgG was positive in the TGI system. Furthermore, as illustrated by the data in Fig. 2 and Table I, there growth (Fig. 2) or goiter size (Table I) (6) . However, we and others (8) (9) (10) (11) (12) (13) (14) have reported that cAMP is indeed a mediator of the growth-promoting action of TSH and therefore probably also of TSAb.
Clearly our findings need have little bearing on claims that there may be a specific "TGI" in other goitrous states (1) (2) (3) (4) or that there are growth pathways mediated by other than cAMP; indeed data have accumulated (10, 11, (24) (25) (26) (27) (28) (29) (30) in accord with the existence of a non-cAMP route for thyroid growth stimulation. Consequently, we restrict interpretation of our current observations to their being in keeping with the view that in Graves' disease, TSAb action, through adenylate cyclase, is sufficient to explain thyroid growth. A role in vivo for other IgG or growth factors is possible. Regarding correlates ofgoiter size with assay data, it is probable that more than a single bioactive substance will influence thyroid growth in an individual patient. Apart from the coexistence of TSAb and other antibodies that affect the TSH receptor (reviewed in 31), it is now recognized that y-interferon may reduce TSH-stimulated thyroid cell metabolism (32) and growth (33) in vitro. It is thus feasible that in vivo, particularly in thyroids with marked lymphocytic infiltration, such action of y-interferon might modulate the size of the goiter.
An important caveat is that in these studies we, and others, speculate on the basis of data obtained with model systems, e.g., FRTL5 cells; a significant achievement will be development of a human thyroid cell line retaining all differentiated functions, including responsiveness to growth stimuli.
